All In Biotech

Drug Trial Radar · NCT07496450

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

A Phase 3, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of mRNA-1018-H5 Pandemic Influenza Vaccine in Adults ≥18 Years of Age

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 4,050 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

4,050

Actual

Start

Mar 23, 2026

Primary completion

Jan 28, 2027

Study completion Jan 28, 2027

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.

Conditions

  • Influenza

Interventions

  • mRNA-1018-H5Biological

    Sterile liquid for injection.

  • PlaceboBiological

    Sterile liquid for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Hemagglutination Inhibition (HAI) Titer ≥ 1:40 at Day 43Time frame: Day 43
  2. Percentage of Participants With Seroconversion at Day 43, as Measured by HAI AssayTime frame: Day 43
  3. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to Day 29 (7 days after each injection)
  4. Number of Participants with Unsolicited Adverse Events (AEs)Time frame: Up to Day 50 (28 days after each injection)
  5. Number of Participants with AEs Leading to Discontinuation, Medically-attended AEs (MAAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs)Time frame: Day 1 to Day 205

Locations

35 sites in 2 countries. Site status is shown where the registry gives one.

  • Velocity Clinical Research, San Bernardino

    San Bernardino, California

  • Velocity Clinical Research, Savannah

    Savannah, Georgia

  • Velocity Clinical Research, Boise

    Meridian, Idaho

  • Velocity Clinical Research, Rockville

    Rockville, Maryland

  • Velocity Clinical Research, Omaha

    Omaha, Nebraska

  • Velocity Clinical Research, Cleveland

    Beachwood, Ohio

  • Velocity Clinical Research, Providence

    East Greenwich, Rhode Island

  • Velocity Clinical Research, Anderson

    Anderson, South Carolina

  • Velocity Clinical Research, Dallas

    Dallas, Texas

  • Velocity Clinical Research, Suffolk

    Suffolk, Virginia

  • Velocity Clinical Research-Bristol

    Bristol, Bristol (Unitary Authority), United Kingdom

  • Velocity Clinical Research - High Wycombe

    High Wycombe, Buckinghamshire, United Kingdom

  • Wansford Research Ltd

    Peterborough, Cambridgeshire, United Kingdom

  • Futuremeds Teesside Middlefield Centre University Hospital of North Tees

    Stockton-on-Tees, County Durham, United Kingdom

  • NIHR Wessex CRDC - Bournemouth Research Hub (Under University Hospital Southampton NHS Foundation Trust)

    Bournemouth, Dorset, United Kingdom

  • NIHR Wessex CRDC - Weymouth Research Hub (Under University Hospital Southampton NHS Foundation Trust)

    Weymouth, Dorset, United Kingdom

  • Panthera Glasgow

    Glasgow, Glasgow City (Scotland), United Kingdom

  • Panthera Enfield

    Enfield, Greater London, United Kingdom

  • Hounslow Medical Centre

    Hounslow, Greater London, United Kingdom

  • hVIVO Services Limited

    London, Greater London, United Kingdom

  • Velocity Clinical Research-North London

    London, Greater London, United Kingdom

  • Accellacare North London

    Northwood, Greater London, United Kingdom

  • Accellacare South London

    Orpington, Greater London, United Kingdom

  • Velocity Clinical Research-Romford

    Romford, Greater London, United Kingdom

  • Panthera Rochdale

    Rochdale, Greater Manchester, United Kingdom

  • NIHR Wessex CRDC - Southampton Research Hub (Under University Hospital Southampton NHS FT)

    Southampton, Hampshire, United Kingdom

  • Fylde Coast Clinical Research at Layton Medical Centre

    Blackpool, Lancashire, United Kingdom

  • FutureMeds Liverpool

    Metropolitan Borough of Wirral, Merseyside, United Kingdom

  • Lakeside Healthcare

    Corby, North Northamptonshire, United Kingdom

  • Panthera York

    York, North Yorkshire, United Kingdom

  • The University of Nottingham Health Service

    Nottingham, Nottinghamshire, United Kingdom

  • Panthera Sheffield

    Sheffield, South Yorkshire, United Kingdom

  • FutureMeds Birmingham Soho Road Health Centre

    Birmingham, West Midlands, United Kingdom

  • Accellacare Warwickshire

    Coventry, West Midlands (Coventry), United Kingdom

  • Accellacare Yorkshire

    Shipley, West Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.